SDGR vs. PCVX, MTSR, TGTX, KRYS, PTCT, ARWR, PTGX, ACLX, AKRO, and KYMR
Should you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include Vaxcyte (PCVX), Metsera (MTSR), TG Therapeutics (TGTX), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), Arcellx (ACLX), Akero Therapeutics (AKRO), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
Schrodinger vs. Its Competitors
Vaxcyte (NASDAQ:PCVX) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Vaxcyte has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.
In the previous week, Vaxcyte had 1 more articles in the media than Schrodinger. MarketBeat recorded 6 mentions for Vaxcyte and 5 mentions for Schrodinger. Vaxcyte's average media sentiment score of 0.85 beat Schrodinger's score of 0.19 indicating that Vaxcyte is being referred to more favorably in the media.
Vaxcyte has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Vaxcyte's return on equity of -16.85% beat Schrodinger's return on equity.
Schrodinger has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.
Vaxcyte presently has a consensus target price of $106.25, suggesting a potential upside of 141.81%. Schrodinger has a consensus target price of $26.29, suggesting a potential upside of 27.54%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Schrodinger.
96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Vaxcyte beats Schrodinger on 10 of the 16 factors compared between the two stocks.
Get Schrodinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrodinger Competitors List
Related Companies and Tools
This page (NASDAQ:SDGR) was last updated on 10/16/2025 by MarketBeat.com Staff
